The identification of mutations of BRAF in human cancers [125] is a milestone, opened new avenues in the therapy of melanoma and was a prerequisite for the development of small molecule BRAF inhibitors, most important vemurafenib and dabrafenib. Here, BRAF is linked to cancer.